Thyrocare Technologies Ltd (IN:THYROCARE)
:THYROCARE
Want to see IN:THYROCARE full AI Analyst Report?
THYROCARE Stock Chart & Stats
₹459.10
-₹16.20(-1.70%)
At close: 4:00 PM EST
₹459.10
-₹16.20(-1.70%)
Day’s Range― - ―
52-Week Range₹316.77 - ₹578.05
Previous CloseN/A
Volume114.81K
Average Volume (3M)56.30K
Market Cap
₹82.75B
Enterprise Value₹26.69B
Total Cash (Recent Filing)₹1.92B
Total Debt (Recent Filing)₹246.80M
Price to Earnings (P/E)50.2
Beta0.62
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.68%
Share Statistics
EPS (TTM)24.16
Shares Outstanding159,165,310
10 Day Avg. Volume44,587
30 Day Avg. Volume56,302
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)9.48
Price to Sales (P/S)6.69
P/FCF Ratio28.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.9
Revenue Forecast (FY)₹9.67B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low debt-to-equity (~0.09) and a strong equity base give the company durable financial flexibility. This supports sustained investment in central labs, buffer through downturns, and low refinancing risk, enabling long-term operational continuity and selective capital allocation.
Strong Cash GenerationHigh cash conversion (FCF-to-net-income ~0.90) and a ~75.5% FCF surge indicate the business reliably turns earnings into cash. This durable cash generation supports reinvestment in automation, network expansion, dividends or buybacks, and reduces reliance on external funding.
Improving Returns & Revenue Re-accelerationRevenue re-acceleration and a near 20% net margin alongside improving ROE (~27.8% in FY2026) reflect enhanced capital efficiency and healthier unit economics. These trends underpin sustainable profitability provided the company maintains utilization and test-mix improvements.
Bears Say
Margin VolatilitySharp year-to-year swings in gross and net margins create uncertainty in projecting long-term profitability. Durable planning for capex, pricing and staffing becomes harder; margin sensitivity to mix, input costs and discounts increases the risk that current margins may not persist.
Volume-dependent ModelBusiness relies on high volumes and collection-network utilization. Sustained revenue and margin levels depend on maintaining sample throughput and volume growth; competition, channel economics or local lab capacity can erode utilization and margins over time.
Rising Balance-sheet Usage & Uneven FCF HistoryA modest increase in leverage, coupled with historically uneven free-cash-flow growth, weakens the otherwise conservative financial position. If FCF reverts or growth slows, higher debt use could constrain reinvestment or increase refinancing risk over the medium term.
Thyrocare Technologies Ltd News
THYROCARE FAQ
What was Thyrocare Technologies Ltd’s price range in the past 12 months?
Thyrocare Technologies Ltd lowest stock price was ₹316.77 and its highest was ₹578.05 in the past 12 months.
What is Thyrocare Technologies Ltd’s market cap?
Thyrocare Technologies Ltd’s market cap is ₹82.75B.
When is Thyrocare Technologies Ltd’s upcoming earnings report date?
Thyrocare Technologies Ltd’s upcoming earnings report date is Aug 04, 2026 which is in 53 days.
How were Thyrocare Technologies Ltd’s earnings last quarter?
Thyrocare Technologies Ltd released its earnings results on May 07, 2026. The company reported ₹3.06 earnings per share for the quarter, missing the consensus estimate of ₹5.4 by -₹2.34.
Is Thyrocare Technologies Ltd overvalued?
According to Wall Street analysts Thyrocare Technologies Ltd’s price is currently Overvalued.
Does Thyrocare Technologies Ltd pay dividends?
Thyrocare Technologies Ltd pays a Quarterly dividend of ₹7 which represents an annual dividend yield of 0.68%. See more information on Thyrocare Technologies Ltd dividends here
What is Thyrocare Technologies Ltd’s EPS estimate?
Thyrocare Technologies Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Thyrocare Technologies Ltd have?
Thyrocare Technologies Ltd has 159,165,310 shares outstanding.
What happened to Thyrocare Technologies Ltd’s price movement after its last earnings report?
Thyrocare Technologies Ltd reported an EPS of ₹3.06 in its last earnings report, missing expectations of ₹5.4. Following the earnings report the stock price went up 1.737%.
Which hedge fund is a major shareholder of Thyrocare Technologies Ltd?
Currently, no hedge funds are holding shares in IN:THYROCARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Thyrocare Technologies Ltd
Thyrocare Technologies Limited, an Indian enterprise, delivers a comprehensive array of diagnostic testing solutions to individual patients, medical laboratories, and healthcare providers throughout the nation. Its operations are structured across three main segments: Diagnostic Testing Services, Imaging Services, and other miscellaneous endeavors. The company's primary focus involves conducting numerous medical diagnostic analyses and specialized test panels aimed at the timely detection and effective management of various health conditions. These include, among others, disorders related to the thyroid, growth, metabolism, autoimmune responses, diabetes, anemia, cardiovascular health, infertility, COVID-19, and a broad spectrum of infectious diseases. Under its "Aarogyam" brand, Thyrocare offers 34 distinct profiles of tests, providing patients with extensive wellness and preventative health check-ups. Furthermore, the company sells "Sugarscan" branded glucometers and glucostrips, along with various consumable products and radiopharmaceuticals. Founded in 1996, Thyrocare Technologies Limited is headquartered in Navi Mumbai, India, and functions as a subsidiary of Docon Technologies Private Limited.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Metropolis Healthcare Ltd.
―
Vijaya Diagnostic Centre Ltd.
―
Vimta Labs Limited
―